Matching the pack still leaves a $585 gap
The easiest way to exaggerate a peptide markup is to compare one expensive vial with one-tenth of a bulk kit. So we started with a stricter question: what happens when both offers contain ten vials, each labeled 10mg?
Listed US warehouse stock
Before conditional promotions
This comparison does not need a market average. It needs two correctly selected packs. The $585 difference is visible in the listings themselves. Whether the difference represents useful service, additional testing or something else requires different evidence.
These are genuine, cropped browser captures. The prices, selected variants and source text have not been altered. Testing claims inside a vendor’s screenshot remain the vendor’s claims; this price review did not validate them.
More vendors reveal several different markets
The wider sweep contains 70 observations across 19 seller or marketplace labels. They describe different purchase arrangements: supplier catalogues, marketplace offers, single-vial storefronts and full kits. Counting all of them together would produce a number with no clear buying meaning.
Three recent US-stock supplier offers—ERP, WBS and HKMS—were $89, $90 and $110 for ten 10mg vials. Their seller-label median is $90. The chart adds storefront and historical observations without pretending they are equally available.
The cheaper outliers need scrutiny too. AoTide’s $63 catalogue figure requires a written quote to establish final price, stock and shipping. Peptaura’s $126.10 Wubei and $158.60 Lumira listings show an in-stock summary, but the detailed cards carry holiday notices through October 8 and October 4 respectively. They are not confirmed immediate-dispatch alternatives.
QSC remains in the comparison at its recorded price. Its September 21 US catalogue offered the kit for $120, plus a separate $20 regional shipping charge: $140 before any tax under those captured terms. Present availability was not re-established. An inactive database entry does not show that the supplier is sold out.
Uther’s $200 observation is historical. The old 10mg product URL returned 404 on October 2, and the current public catalogue returned 89 products without a retatrutide listing. Its per-product dispatch origin was unspecified. We retain the September 1 price without calling it a live offer.
The complete comparison tables keep those limitations beside every price. A short list is easier to read; a source ledger is what makes it auditable.
ERP and WBS change how we should read the median
There is a problem with presenting $90 as a benchmark from three independent sources: our own ERP/WBS/JKL investigation connects two of those seller labels.
That investigation documented shared storefront infrastructure, catalog fingerprints, product codes and a repeated price ladder. It supports treating the names as a connected supply network. It does not identify a single legal owner or manufacturing facility, and it does not make each vendor’s test results interchangeable.
The three-label median is $90. Retaining either ERP or WBS, plus HKMS, changes the two-observation median to $99.50 or $100. This is a sensitivity check, not a finding that two independent factories remain.
We therefore show what happens when the cohort is widened and when one connected label is omitted:
| Benchmark for ten × 10mg | Retained labels | Median |
|---|---|---|
| Recent US-stock offers: ERP, WBS, HKMS | 3 | $90 |
| Recent offers, omit either ERP or WBS | 2 | $99.50–$100 |
| Add dated GYC ($100) and QSC ($120) US offers | 5 | $100 |
| Wider set, omit either ERP or WBS | 4 | $105 |
The wider set includes September 15 and September 21 observations whose present availability is unconfirmed. No version is a random sample or a verified count of independent manufacturers. JKL is not inserted into the price cohort without a qualifying price observation.
At $105 instead of $90, Synthrex’s advertised $675 kit is still $570 more, or 543% higher. The $90 headline is sensitive to which labels we count. The existence of a large price gap in these selected offers is much less sensitive.
Discounts narrow the gap. They need their own evidence.
The checkout total matters more than a crossed-out price. Crush’s displayed sale is included below; unverified coupons are shown as conditional calculations.
| Ten × 10mg listing | Item price | Extra vs $105 | Percentage higher |
|---|---|---|---|
| Crush · sale, unavailable | $269.10 | $164.10 | 156% |
| Jonezie · before coupon | $473.38 | $368.38 | 351% |
| Synthrex · before promotions | $675.00 | $570.00 | 543% |
The $105 benchmark is the wider, dated four-label sensitivity case above. It is not a delivered price or an independent-source market estimate. These percentages are price premiums, not profit margins: neither the supplier asking price nor a storefront reveals the reseller’s acquisition cost or expenses.
Jonezie advertises FALL25 for 25% off. If applicable to the ten-pack, $473.38 becomes $355.04, or $250.04 above the $105 benchmark—about 238% higher. Its separate 30% email-signup offer was not combined with that code; eligibility and stacking were not verified.
Inspect Jonezie's product page.
Synthrex advertises 10%, 15% and 20% stack discounts, depending on quantity. The selected ten-vial kit still displayed $675. We could not establish whether a kit counts as one item or ten vials, or whether another discount stacks. Even an illustrative 20% reduction would leave $540, about 414% above $105. That is a sensitivity calculation, not an available checkout price.
Shipping changes the final comparison too. Crush advertises free shipping above $200; supplier shipping is not necessarily included. But an unavailable $269.10 listing is not a current purchase option, regardless of its shipping offer.
A smaller order is a service. A better product needs proof.
The strongest argument for a reseller is often the transaction itself: customers can buy a smaller quantity, use a familiar payment method and deal with a storefront. Those conveniences can have value even when the price per milligram is higher.
The sources give concrete examples. Jonezie describes order review followed by an invoice. Regenerative Research advertises UPS 2nd Day Air and dispatch within 24 hours. LabFirst lists California fulfillment. These are published service terms, not delivery performance we measured.
Single-vial pricing illustrates that tradeoff. Regenerative Research lists one 10mg vial at $90; WBS lists ten at $90. The same item spend buys ten times the labeled quantity in the supplier offer. But a single-vial customer may be buying a smaller commitment and a different service. Multiplying a single-vial price by ten would not establish the reseller’s actual kit price.
For full-kit comparisons, the smaller-order explanation falls away: both offers already require ten vials. US dispatch alone cannot explain the distinction either, because the supplier cohort is explicitly US-stock. That leaves the seller’s particular testing, fulfillment and customer service to justify the difference.
The quality premium has to be demonstrated.
A useful explanation would connect the money to evidence a customer can inspect:
Which offered lot was tested, who selected the vials, how many were sampled, and how much did their measured contents vary?
How many lots arrived, were tested and were rejected? What happened to rejected stock? Passing certificates alone cannot supply that denominator.
What dispatch performance, payment terms and remedies for missing, damaged or disputed orders does the customer actually receive?
These price sources cannot allocate a seller’s premium among testing, payment processing, inventory losses, support and profit. Nor does a missing public failure report prove concealment. The evidence needed is a documented process and its outcomes—not an assumed cost structure.
Purity cannot fill the missing link
Adding a vendor’s average purity beside its price would make an attractive comparison. It would also join two different populations unless the reports actually cover the lots being offered.
This review has not matched every price to the current shipment’s batch, measured amount and contamination panel. A vendor-wide average cannot establish that link. Purity and quantity also answer different questions: a high-purity sample can contain less peptide than its label states. Neither alone is a complete safety assessment.
The next useful step is to identify the offered lot, inspect its source report and establish what was measured. Our retatrutide report collection and comparison of peptide laboratory methods support that investigation. They do not turn a matching name or label into evidence of pharmaceutical equivalence.
Inspect the complete price record
The main exhibits isolate the argument. These reference tables preserve the wider vendor sweep, including offers that do not belong in the recent US-stock benchmark. All are USD item prices; observation dates and availability remain part of the comparison.
All additional ten-by-10mg storefront offers
| Seller or listing source | Ten × 10mg item price | Per-vial equivalent | What the October 2 check establishes |
|---|---|---|---|
| AoTide | $63.00 | $6.30 | Informational catalogue price; final price, stock and shipping require a written quote |
| Wubei Chemicals via Peptaura | $126.10 | $12.61 | Summary says in stock; detailed card says holiday until Oct 8 |
| Lumira via Peptaura | $158.60 | $15.86 | Summary says in stock; detailed card says holiday until Oct 4 |
| Crush Research | $269.10 | $26.91 | Displayed sale included; product currently unavailable |
| Jonezie Labs | $473.38 | $47.34 | Listed in stock; order request followed by an invoice; before advertised coupon |
| Synthrex Biotech | $675.00 | $67.50 | Product page says in stock; advertised promotions not applied |
QSC, Uther and the older supplier observations
| Supplier | Ten × 10mg item price | Listed dispatch | Price observation / present limitation |
|---|---|---|---|
| QSC | $120 | US | Sep 21 bot catalogue; current availability not re-established |
| GYC | $100 | US | Sep 15 storefront capture; current availability not re-established |
| Uther | $200 | Unspecified per product | Sep 1 storefront capture; old 10mg page returned 404 on Oct 2 |
| BAOHUA | $80 | China | Aug 15 price-list record; historical, not a current quote |
| FSD | $100 | US | Aug 13 price-list record; historical, not a current quote |
| TFC | $100 | US | Aug 11 price-list record; historical, not a current quote |
Single 10mg vials: $44.10 to $90 advertised
| Storefront | One 10mg vial | Price per labeled mg | Availability / price basis |
|---|---|---|---|
| Crush | $44.10 | $4.41 | Sale price; unavailable |
| Jonezie | $57.18 | $5.72 | In stock; before coupon; invoice after order review |
| The Pep Labs | $72.90 | $7.29 | Page says in stock |
| Synthrex | $79.00 | $7.90 | Page says in stock; advertised promotions not applied |
| LabFirst | $85.00 | $8.50 | Single-vial list price; page says in stock |
| Regenerative Research, RR-RT | $90.00 | $9.00 | Page says in stock; batch RT26-09 |
These are advertised single-vial prices, not ten-vial kit quotes. Crush is unavailable. Conditional promotions, shipping and tax are not included. LabFirst also lists a $76.50 tier for 10–19 vials and a buy-one-get-one-half-price offer; stacking was not verified.
Other strengths: Peptide Partners and the supplier price ladder
| Advertised pack | Total labeled amount | Item price | Per labeled mg |
|---|---|---|---|
| 2 × 12mg | 24mg | $124 | $5.17 |
| 10 × 12mg | 120mg | $545 | $4.54 |
| 2 × 24mg | 48mg | $230 | $4.79 |
| 10 × 24mg | 240mg | $880 | $3.67 |
The 12mg ten-pack is approximately $45.42 per 10mg equivalent. That is a normalization, not a 10mg vial the business offers or a $45.42 checkout. Its $545 commitment and 120mg total stay visible.
Vial strength also changes the supplier benchmark. The following are all ten-vial kits; each cell shows kit price / price per labeled mg:
| Supplier and observation | 10mg per vial | 20mg per vial | 30mg per vial |
|---|---|---|---|
| ERP, Oct 2; US stock | $89 / $0.89 | $149 / $0.75 | $179 / $0.60 |
| WBS, Oct 2; US stock | $90 / $0.90 | $150 / $0.75 | $180 / $0.60 |
| HKMS, Sep 29; US stock | $110 / $1.10 | $180 / $0.90 | $250 / $0.83 |
| QSC, Sep 21; historical US catalogue | $120 / $1.20 | $200 / $1.00 | $250 / $0.83 |
WBS’s 30mg kit has three times the labeled quantity of its 10mg kit for twice the item price. Its price per labeled mg falls by one-third. A pooled “retatrutide average” that mixes strengths would hide that difference. A historical average that mixes price dates would add another distortion. Neither should replace a defined pack comparison.
Download the full 70-row ledger for every retained variant and its source. The live retatrutide price index uses its own displayed cohort and price basis; it may differ from this frozen research snapshot.
How we checked the prices
Scope. This is a purposive, nonrandom comparison of 70 asking-price observations across 19 seller or marketplace labels. It is not 19 confirmed independent manufacturers, a whole-market average or a purchasing recommendation. No order, payment or independent quality test was performed.
Selection. The recent supplier cohort requires an exact ten-by-10mg offer, US dispatch, observation on or after September 25 and an in-stock source state. Quarantined, rejected and pending-review records are excluded. ERP and WBS qualify through October 2 storefront observations; HKMS qualifies through a September 29 supplier price-list capture. One offer per label is retained. Their mean is $96.33 and median $90.
The wider September 2–October 2 window adds GYC’s September 15 $100 and QSC’s September 21 $120 US observations, giving a $101.80 mean and $100 median, with present availability unconfirmed for those older offers. The connected-label sensitivity cases remove either ERP or WBS; they do not merge their records, transfer test results or assume the remaining labels are independent.
Exclusions and source limits. ERP’s China-dispatch ten-by-10mg observation is $84, only $5 below its US-stock $89 before shipping. It is excluded from the US benchmark. Uther’s dispatch origin is unresolved. HM Peptide’s recent $106 row remains pending review and is excluded. Marketplace labels are not assumed independent of other sources. Reading an old database row does not refresh its observation date.
Provenance. Public storefront URLs, dates, price basis and availability notes accompany each row where available. Some retained supplier catalogues and price lists are not public web pages; their price observations are included in the CSV without publishing private messages or contact details. The October 2 WBS, Synthrex and Jonezie screenshots are genuine browser captures cropped to the product controls, with source text unchanged.
Arithmetic. Per-vial price is item price divided by vial count. Price per labeled milligram is item price ÷ (vial count × labeled milligrams per vial). Percentage higher is (comparison price − benchmark) ÷ benchmark × 100. Medians of even-sized sets average the two middle observations. Calculations use unrounded inputs; displayed percentages round to the nearest whole number. Values use labeled content, not measured fill.
Displayed sales are included. Conditional coupons stay separate. Shipping and tax are excluded unless explicitly discussed. No TitrateLab checkout markup is added to a supplier price. Supplier asking price is not factory cost, and a common code or label does not establish an identical batch.
Identity. The FBI’s warning about brand impersonation in search advertising explains why a familiar name or prominent search result does not authenticate a vendor contact. Inclusion here attributes a dated price source; it does not establish present ownership or control, fulfillment or product quality.
Revision, October 2. Expanded the original three-supplier/Crush snapshot into a 19-label review, added selected-pack source captures and coupon checks, and incorporated the ERP/WBS network connection into benchmark sensitivity. The June 29 “same vial” and broad markup claims remain withdrawn. Matching labels and historical prices do not establish identical products.
Prepared by the TitrateLab Research Desk with AI-assisted extraction and arithmetic checks. Next price review: October 9, or sooner if a material source correction changes the comparison. Submit evidence through our methodology and corrections page.
